1,000
Participants
Start Date
January 1, 2012
Primary Completion Date
March 1, 2023
Study Completion Date
June 1, 2024
Biologic therapy for psoriasis
Exposure to systemic biologic drugs for psoriasis, including TNF inhibitors (etanercept, adalimumab, infliximab, certolizumab), IL-12/23 inhibitors (ustekinumab), IL-17 inhibitors (secukinumab, ixekizumab, brodalumab), and IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab). Treatments were prescribed as part of routine clinical care.
Department of Dermatology, Reina Sofia University Hospital, Córdoba
Hospital Universitario Reina Sofia de Cordoba
OTHER_GOV
Universidad de Córdoba
OTHER
Maimonides Institute for Biomedical Research of Cordoba (IMIBIC)
UNKNOWN
Juan Ruano Ruiz
OTHER